Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease
ObjectiveMatrix metalloproteinases (MMPs) are essential for tissue formation, neuronal network remodeling, and blood–brain barrier integrity. MMPs have been widely studied in acute brain diseases. However, the relationship with Parkinson’s disease (PD) remains unclear. The purpose of this study was...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.889257/full |
| _version_ | 1818516982023061504 |
|---|---|
| author | Chuan Ze Liu Chuan Ze Liu Da Shuai Guo Da Shuai Guo Jian Jun Ma Jian Jun Ma Jian Jun Ma Lin Rui Dong Lin Rui Dong Qing Qing Chang Qing Qing Chang Hong Qi Yang Hong Qi Yang Hong Qi Yang Ke Ke Liang Ke Ke Liang Xiao Huan Li Xiao Huan Li Da Wei Yang Da Wei Yang Yong Yan Fan Yong Yan Fan Qi Gu Qi Gu Qi Gu Si Yuan Chen Si Yuan Chen Si Yuan Chen Dong Sheng Li Dong Sheng Li Dong Sheng Li |
| author_facet | Chuan Ze Liu Chuan Ze Liu Da Shuai Guo Da Shuai Guo Jian Jun Ma Jian Jun Ma Jian Jun Ma Lin Rui Dong Lin Rui Dong Qing Qing Chang Qing Qing Chang Hong Qi Yang Hong Qi Yang Hong Qi Yang Ke Ke Liang Ke Ke Liang Xiao Huan Li Xiao Huan Li Da Wei Yang Da Wei Yang Yong Yan Fan Yong Yan Fan Qi Gu Qi Gu Qi Gu Si Yuan Chen Si Yuan Chen Si Yuan Chen Dong Sheng Li Dong Sheng Li Dong Sheng Li |
| author_sort | Chuan Ze Liu |
| collection | DOAJ |
| description | ObjectiveMatrix metalloproteinases (MMPs) are essential for tissue formation, neuronal network remodeling, and blood–brain barrier integrity. MMPs have been widely studied in acute brain diseases. However, the relationship with Parkinson’s disease (PD) remains unclear. The purpose of this study was to evaluate the serum MMP3 and MMP9 levels of PD patients and analyze their correlation with non-motor symptoms.MethodsIn this cross-sectional study, we recruited 73 patients with idiopathic PD and 64 healthy volunteers. Serum MMP3 and MMP9 levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients with PD were assessed for non-motor symptoms using the Non-motor Symptoms Scale (NMSS) and Parkinson’s disease sleep scale (PDSS) and Mini Mental State Examination (MMSE).ResultsSerum MMP3 levels were significantly decreased in PD patients, predominantly those with early-stage PD, compared with controls [12.56 (9.30, 17.44) vs. 15.37 (11.33, 24.41) ng/ml; P = 0.004], and the serum MMP9 levels of PD patients were significantly higher than those of healthy controls [522 (419, 729) vs. 329 (229, 473) ng/ml; P < 0.001]. MMP3 levels were positively correlated with the NMSS total score (r = 0.271, P = 0.020) and the single-item scores for item six, assessing the gastrointestinal tract (r = 0.333, P = 0.004), and there was an inverse correlation between serum MMP3 levels and PDSS score (r = –0.246, P = 0.036); meanwhile, MMP9 levels were positively correlated with the NMSS total score (r = 0.234, P = 0.047), and higher serum MMP9 levels were detected in the cognitive dysfunction subgroup than in the cognitively intact subgroup [658 (504, 877) vs. 502 (397, 608) ng/ml, P = 0.008].ConclusionThe serum MMP3 level of PD patients (especially early-stage patients) was significantly lower than that of the healthy control group, and the MMP9 level was significantly higher than that of the healthy control group. MMP3 and MMP9 levels correlate with sleep disturbance and cognitive function in PD patients, respectively. |
| first_indexed | 2024-12-11T00:49:51Z |
| format | Article |
| id | doaj.art-1ef863cef0ba4d5d859719e33237e996 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-11T00:49:51Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-1ef863cef0ba4d5d859719e33237e9962022-12-22T01:26:39ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-08-011410.3389/fnagi.2022.889257889257Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s diseaseChuan Ze Liu0Chuan Ze Liu1Da Shuai Guo2Da Shuai Guo3Jian Jun Ma4Jian Jun Ma5Jian Jun Ma6Lin Rui Dong7Lin Rui Dong8Qing Qing Chang9Qing Qing Chang10Hong Qi Yang11Hong Qi Yang12Hong Qi Yang13Ke Ke Liang14Ke Ke Liang15Xiao Huan Li16Xiao Huan Li17Da Wei Yang18Da Wei Yang19Yong Yan Fan20Yong Yan Fan21Qi Gu22Qi Gu23Qi Gu24Si Yuan Chen25Si Yuan Chen26Si Yuan Chen27Dong Sheng Li28Dong Sheng Li29Dong Sheng Li30Department of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurology, Zhengzhou University People’s Hospital, Zhengzhou, ChinaObjectiveMatrix metalloproteinases (MMPs) are essential for tissue formation, neuronal network remodeling, and blood–brain barrier integrity. MMPs have been widely studied in acute brain diseases. However, the relationship with Parkinson’s disease (PD) remains unclear. The purpose of this study was to evaluate the serum MMP3 and MMP9 levels of PD patients and analyze their correlation with non-motor symptoms.MethodsIn this cross-sectional study, we recruited 73 patients with idiopathic PD and 64 healthy volunteers. Serum MMP3 and MMP9 levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients with PD were assessed for non-motor symptoms using the Non-motor Symptoms Scale (NMSS) and Parkinson’s disease sleep scale (PDSS) and Mini Mental State Examination (MMSE).ResultsSerum MMP3 levels were significantly decreased in PD patients, predominantly those with early-stage PD, compared with controls [12.56 (9.30, 17.44) vs. 15.37 (11.33, 24.41) ng/ml; P = 0.004], and the serum MMP9 levels of PD patients were significantly higher than those of healthy controls [522 (419, 729) vs. 329 (229, 473) ng/ml; P < 0.001]. MMP3 levels were positively correlated with the NMSS total score (r = 0.271, P = 0.020) and the single-item scores for item six, assessing the gastrointestinal tract (r = 0.333, P = 0.004), and there was an inverse correlation between serum MMP3 levels and PDSS score (r = –0.246, P = 0.036); meanwhile, MMP9 levels were positively correlated with the NMSS total score (r = 0.234, P = 0.047), and higher serum MMP9 levels were detected in the cognitive dysfunction subgroup than in the cognitively intact subgroup [658 (504, 877) vs. 502 (397, 608) ng/ml, P = 0.008].ConclusionThe serum MMP3 level of PD patients (especially early-stage patients) was significantly lower than that of the healthy control group, and the MMP9 level was significantly higher than that of the healthy control group. MMP3 and MMP9 levels correlate with sleep disturbance and cognitive function in PD patients, respectively.https://www.frontiersin.org/articles/10.3389/fnagi.2022.889257/fullParkinson’s diseasematrix metallopeptidase 3matrix metallopeptidase 9nonmotor symptomcross-sectional study |
| spellingShingle | Chuan Ze Liu Chuan Ze Liu Da Shuai Guo Da Shuai Guo Jian Jun Ma Jian Jun Ma Jian Jun Ma Lin Rui Dong Lin Rui Dong Qing Qing Chang Qing Qing Chang Hong Qi Yang Hong Qi Yang Hong Qi Yang Ke Ke Liang Ke Ke Liang Xiao Huan Li Xiao Huan Li Da Wei Yang Da Wei Yang Yong Yan Fan Yong Yan Fan Qi Gu Qi Gu Qi Gu Si Yuan Chen Si Yuan Chen Si Yuan Chen Dong Sheng Li Dong Sheng Li Dong Sheng Li Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease Frontiers in Aging Neuroscience Parkinson’s disease matrix metallopeptidase 3 matrix metallopeptidase 9 nonmotor symptom cross-sectional study |
| title | Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease |
| title_full | Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease |
| title_fullStr | Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease |
| title_full_unstemmed | Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease |
| title_short | Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease |
| title_sort | correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non motor symptoms in patients with parkinson s disease |
| topic | Parkinson’s disease matrix metallopeptidase 3 matrix metallopeptidase 9 nonmotor symptom cross-sectional study |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.889257/full |
| work_keys_str_mv | AT chuanzeliu correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT chuanzeliu correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT dashuaiguo correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT dashuaiguo correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT jianjunma correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT jianjunma correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT jianjunma correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT linruidong correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT linruidong correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT qingqingchang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT qingqingchang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT hongqiyang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT hongqiyang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT hongqiyang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT kekeliang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT kekeliang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT xiaohuanli correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT xiaohuanli correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT daweiyang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT daweiyang correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT yongyanfan correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT yongyanfan correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT qigu correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT qigu correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT qigu correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT siyuanchen correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT siyuanchen correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT siyuanchen correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT dongshengli correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT dongshengli correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease AT dongshengli correlationofmatrixmetalloproteinase3andmatrixmetalloproteinase9levelswithnonmotorsymptomsinpatientswithparkinsonsdisease |